Abstract
Background COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern.
Methods We conducted a global Phase 3, multi-stage efficacy study (NCT04904549) among adults aged ≥18 years. Participants were randomized 1:1 to receive two intramuscular injections 21 days apart of a bivalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (5 μg of ancestral (D614) and 5 μg of B.1.351 [beta] variant spike protein) or placebo. Symptomatic COVID-19 was defined as laboratory-confirmed COVID-19 with COVID-19-like illness (CLI) symptoms. The primary efficacy endpoint was the prevention of symptomatic COVID-19 ≥14 days after the second injection (post-dose 2 [PD2]).
Results Between 19 Oct 2021 and 15 Feb 2022, 12,924 participants received ≥1 study injection. 75% of participants were SARS-CoV-2 non-naïve. 11,416 participants received both study injections (efficacy-evaluable population [vaccine, n=5,736; placebo, n=5,680]). Up to 15 March 2022, 121 symptomatic COVID-19 cases were reported (32 in the vaccine group and 89 in the placebo group) ≥14 days PD2 with a vaccine efficacy (VE) of 64.7% (95% confidence interval [CI] 46.6; 77.2%). VE was 75.1% (95% CI 56.3; 86.6%) in non-naïve and 30.9% (95% CI -39.3; 66.7%) in naïve participants. Viral genome sequencing identified the infecting strain in 68 cases (Omicron [BA.1 and BA.2 subvariants]: 63; Delta: 4; Omicron and Delta: 1). The vaccine was well-tolerated and had an acceptable safety profile.
Conclusions A bivalent vaccine conferred heterologous protection against symptomatic infection with newly emergent Omicron (BA.1 and BA.2) in non-naïve adults 18–59 years of age.
ClinicalTrials.gov NCT04904549
Competing Interest Statement
GHD, MIB, BF, M-HG, CAG, RMC, SS are Sanofi employees. MIB, BF, M-HG, CAG, RMC, SS hold stock or stock options in Sanofi. SS hold patents pending on COVID-19 vaccine. RMC has Received institutional funding from BARDA for the present study; has received support for attending meetings and/or travel from Sanofi; and holds patents planned, issued or pending from Sanofi. M-HG has received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Sanofi. NR has received institutional funding from the National Institutes of Health; and institutional grants or contracts from Merck, Sanofi, Quidel, Pfizer and Lilly. SRW has received institutional funding from Sanofi and the National Institute of Allergy and Immunology/National Institutes of Health; and institutional grants or contracts from Janssen Vaccines/Johnson & Johnson, Moderna Tx, Vir Biotechnology and Worcester HIV vaccine; has participated on data safety monitoring or advisory boards for Janssen Vaccines/Johnson & Johnson; and his spouse holds stock/stock options in Regeneron Pharmaceuticals. NG has received institutional funding from Sanofi, GSK and the National Institute of Allergy and Immunology/National Institutes of Health; and is in receipt of grants or contracts from the NIH/NIAID/DAIDS. MA is an employee of the NIAID, which funded aspects of the current study. MAC and MK are employees of GSK and owns shares in the GSK group of companies. LS is an employee of the GSK group of companies. MJ and JJK have received institutional support from Sanofi and the NIAID/NIH with respect to this study. MLR has received institutional support/contracts for the present manuscript from WRAIR IPA and the US Medical Research and Development Command. MA is an employee of the NIAID, which funded aspects of the current study; The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI 68614HVTN), the Statistics and Data Management Center (UM1 AI 68635), the HVTN Laboratory Center (UM1 AI 68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI 68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI 68636), and the Infectious Diseases Clinical Research Consortium leadership group 5 (UM1 AI 148684-03). SSa was a Sanofi employee at the time of study conduct; and holds patents planned, issued of pending on COVID-19 vaccines. AC, JA KPA, ASB, TB, DD, MKJ, HK, RM, NM, HR, SMVM, FS, JT, TAW, SG have no interests to declare.
Clinical Trial
NCT04904549
Funding Statement
Funding was provided by Sanofi and by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services under contract number HHSO100201600005I, and in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under contract number W15QKN-16-9-1002. The views presented here are those of the authors and do not purport to represent those of the Department of the Army. This work was done in collaboration with GSK, who provided access to, and use of, the AS03 Adjuvant System. The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI 68614HVTN), the Statistics and Data Management Center (UM1 AI 68635), the HVTN Laboratory Center (UM1 AI 68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI 68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI 68636), and the Infectious Diseases Clinical Research Consortium leadership group 5 (UM1 AI 148684-03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in compliance with the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The protocol and amendments were approved by applicable Independent Ethics Committees/Institutional Review Boards and per local regulations. Approval was received by the following Independent Ethics Committees/Institutional Review Boards. Colombia: Comite de Etica en Investigacion CAIMED (approved); Comite de Etica en Investigacion de la Fundacion del Caribe para la Investigacion Biomedica (approved); Comite de Etica en Investigacion VITA (approved); Corporacion Cientifica Pediatrica Comite de Etica en Investigacion Biomedica (approved); Comite de Etica en investigacion de la Division Ciencias de la Salud de la Universidad del Norte (approved); Comite de Etica en Investigacion Clinica de la Costa (approved). Ghana: Kwame Nkrumah University of Science and Technology Committee on Human Research, Publication and Ethics (approved); Kintampo Health Research Centre Institutional Ethics Committee (approved); Navrongo Health Research Centre Institutional Review Board (approved); Ghana Health Service Ethics Review Committee (approved). India: Institute of Medical Sciences and Sum Hospital Institutional Ethics Committee (approved); Jawahar Lal Nehru Medical College Institutional Ethics Committee (approved); Vidharba Institute of Medical Sciences - Nagpur Institutional Ethics Committee (approved); Jeevan Rekha Hospital Institutional Ethics Committee (approved); SRM Medical College Hospital and Research Centre Institutional Ethics Committee (approved); Prakhar Hospital Institutional Ethics Committee (approved); All India Institute of Medical Sciences Patna Institutional Ethics Committee (approved); Aartham Ethics Committee - Aartham Multi Super Speciality Hospital (approved); Maharaja Agrasen Superspeciality Hospital Institutional Ethics Committee (approved). Kenya: Kenya Medical Research Scientific & Institute Ethics Review Unit (approved); Kenyatta National Hospital - University of Nairobi - College of Health Sciences Ethics Review Committee (approved); The Aga Khan University - Nairobi Institutional Ethics Review Committee (approved); Institutional Review Ethics Committee MOI University College of Health - MOI Teaching and Referral Hospital (approved); National Commission for Science Technology and Innovation (approved). Mexico: Comite de Etica en Investigacion de la Direccion de Investigacion del Instituto Nacional de Pediatria; Comite de Etica en Investigacion de Medica Sur (approved); Comite de Etica en Investigacion Hospital Aranda de la Parra (approved); Comite de Etica en Investigacion Hospital Civil de Guadalajara - Sub-Direccion de Ensenanza e Investigacion (approved); Comite de Etica en Investigacion de Investigacion Biomedica para el Desarrollo de Farmacos (approved). Nepal: Tribhuvan University Institute of Medicine Institutional Review Committee (approved); Kathmandu University School of Medical Sciences Institutional Review Board (approved); Nepalgunj Medical College Teaching Hospital Institutional Review Committee (approved). Uganda: Uganda Virus Research Institute (approved); London School of Hygiene and Tropical Medicine Research Ethics Committee (approved). Ukraine: Blagomed Medical Clinic LLC Ethics Commission (approved); Edelweiss Medics LLC (approved); Center of Family Medicine Plus LLC Ethical Committee (approved); Medbud Clinic LLC Ethical Committee (approved). All participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ Affiliation at time of study
Data Availability
Qualified researchers can request access to patient-level data and related study documents, including the clinical study report, study protocol with any amendments, blank case report forms, statistical analysis plan, and dataset specifications. Patient-level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at https://vivli.org/.